Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase
Authors:
Open Access
- 1 February 2016
- journal article
- clinical trial
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 117 (2) , 164-171
Abstract
No abstract availableKeywords
Funding Information
- Shire
- National Institutes of Health (UL1 TR000004)
This publication has 19 references indexed in Scilit:
- Long-term effect of imiglucerase in Latin American children with Gaucher disease type 1: lessons from the International Collaborative Gaucher Group Gaucher RegistryBMC Hematology, 2014
- Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 studyAmerican Journal of Hematology, 2013
- Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher diseaseAmerican Journal of Hematology, 2012
- How I treat Gaucher diseaseBlood, 2011
- Management of neuronopathic Gaucher disease: Revised recommendationsJournal of Inherited Metabolic Disease, 2009
- Eight-Year Clinical Outcomes of Long-Term Enzyme Replacement Therapy for 884 Children With Gaucher Disease Type 1Pediatrics, 2008
- The Clinical and Demographic Characteristics of Nonneuronopathic Gaucher Disease in 887 Children at DiagnosisArchives of Pediatrics & Adolescent Medicine, 2006
- Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statementsEuropean Journal of Pediatrics, 2004
- The Gaucher RegistryArchives of internal medicine (1960), 2000
- Analysis and Classification of 304 Mutant Alleles in Patients with Type 1 and Type 3 Gaucher DiseaseThe American Journal of Human Genetics, 2000